Printer friendly
Acronymfinder

What does ECTRIMS stand for?

ECTRIMS stands for European Committee for Treatment and Research in Multiple Sclerosis


This definition appears very rarely and is found in the following Acronym Finder categories:

  • Science, medicine, engineering, etc.
  • Organizations, NGOs, schools, universities, etc.

Other Resources:
We have 1 other definition for ECTRIMS in our Acronym Attic

Samples in periodicals archive:

The study, which included patients receiving either COPAXONE([R]), Avonex([R]) (IFN-[eth]-1a IM), Betaseron([R]) (IFN-[eth]-1b SC), or Rebif([R]) (IFN-[eth]-1a SC), was presented last week at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), in Madrid, Spain.
Data presented last week at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain, showed that COPAXONE([R]) (glatiramer acetate injection) may slow the neurodegenerative tissue damage that is a key aspect of multiple sclerosis (MS) disease pathology.
Initial findings presented today at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain showed that treatment with AVONEX (Interferon beta-1a) promoted a statistically significant recovery of T1-black hole lesion volume by almost 24% (p<0.
These data, presented at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain, contribute to existing data which demonstrate the overall therapeutic benefits of TYSABRI, including its significant impact on relapse reduction, disability progression and MRI measures.
JERUSALEM -- New data presented today at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain, showed that antibodies to COPAXONE([R]) (glatiramer acetate injection) developed in all patients with multiple sclerosis (MS) treated with COPAXONE([R]), but did not interfere with the efficacy of the drug.
OTCBB:PFTR), a company involved in the development and commercialization of cell therapies, presented positive interim research findings of its Phase I/II clinical trials of Tovaxin(TM), a novel T cell therapeutic vaccine for Multiple Sclerosis on Friday, September 30, 2005, at the 21st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 10th Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) congress held in Thessaloniki, Greece.
In a long-term, open-label, compassionate use study of up to 26 years (prior to any immune modulating therapies approved by the Food and Drug Administration (FDA)), presented at the 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), clinical efficacy and safety data demonstrated reductions in relapse rates, slowed disease progression, and continued tolerability of COPAXONE(R).